Treatment options when breast cancer becomes unresponsive to chemotherapy
UC expert speaks with Everyday Health
The University of Cincinnati's Mahmoud Charif was featured in an Everyday Health article discussing treatment options when metastatic triple-negative breast cancer (mTNBC) becomes unresponsive to chemotherapy.
Even though chemotherapy is the standard treatment for mTNBC, it’s not uncommon for these drugs to stop working eventually.
Charif, MD, a University of Cincinnati Cancer Center member, associate professor in the UC College of Medicine and a UC Health physician, said breast cancer cells can become resistant to chemotherapy over time, making the treatment less effective. This is especially the case for mTNBC, which is typically a more aggressive form of cancer.
Treatment options when mTNBC becomes unresponsive to chemotherapy include immunotherapy, clinical trials and a class of drugs called antibody-drug conjugates (ADCs). Charif explained ADCs combine an antibody therapy and chemotherapy to work together to kill cancer cells.
Read the Everyday Health article.
Featured photo of 3D breast cancer cell courtesy of the National Cancer Institute.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.